DPTX3186 in Wnt Pathway Activated Solid Tumors
Recruiting now · Phase 1
Conditions studied: Solid Tumors
In brief
This is a first-in human clinical study of DPTX3186 in subjects with Wnt-pathway activated solid tumors where no other treatments exist. The study will evaluate safety, pharmacokinetics, and initial activity of DPTX3186, as well as explore pharmacodynamic parameters to identify potential biomarkers of efficacy
Key facts
- Study ID
- NCT07312903
- Run by
- Dewpoint Therapeutics
- People needed
- 40
- Starts
- 2026-01-01
- Expected to finish
- 2028-06-30
- Last updated by the study team
- 2026-01-12
Who can join
Age: 18 and older. Sex: any. Healthy volunteers: not accepted.
You may qualify if…
- Histologically or cytologically confirmed solid tumor and tumor types known to be Wnt-pathway activated (such as colorectal cancer, gastric cancer, lung cancer, and triple negative breast cancer) and no other approved treatment options available.
- At least one measurable target lesion as defined by RECIST v1.1 on CT, PET/CT, or MRI.
- ECOG performance status of 0 or 1.
- Physiological conditions that may prevent absorption of an oral medication including but not limited to colostomy and ileostomy.
- Age ≥18 years (or ≥ age of majority per local regulation)
- Life expectancy ≥3 months
- Willing and able to comply with protocol requirements
You may not qualify if…
- Symptomatic or uncontrolled brain metastasis requiring concurrent treatment,
- Another known malignancy that is progressing or requires active treatment within the last 2 years (except basal cell carcinoma, in situ cervical cancer, etc.).
- Inadequate organ function
- Known hypersensitivity to study drug or excipients
Where it is running
- NEXT San Antonio — San Antonio, Texas, United States (enrolling)
- NEXT Virginia — Fairfax, Virginia, United States (enrolling)
Full record on ClinicalTrials.gov
Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.